CKPT(Delisted)
Checkpoint·NASDAQ
--
--(--)
Signals Analysis
Bullish signal 1
Bearish signal 1
EPS Beats Expectation
Consecutive Revenue Decline
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CKPT
Checkpoint Therapeutics, Inc.
A clinical-stage immunotherapy and targeted oncology company that developing treatments for solid tumor cancers
95 Sawyer Road, Suite 110, Waltham, Massachusetts 02453
--
Checkpoint Therapeutics, Inc., was incorporated in Delaware on November 10, 2014. The Company is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of new therapies for patients with solid tumor cancer. The Company is evaluating its lead antibody candidate, cosibelimab, an anti-programmed death ligand 1 (" PD-L1 ") antibody licensed by the Dana-Farber Cancer Institute (" Dana-Farber "), in a global, open-label, multi-cohort Phase 1 clinical trial for the checkpoint treatment of newly diagnosed patients with specific relapsed or metastatic cancers, This includes an ongoing cohort of locally advanced and metastatic skin squamous cell carcinoma (" CSCC ") designed to support one or more marketing approval applications.
Company Financials
EPS
CKPT has released its 2025 Q1 earnings. EPS was reported at -0.19, versus the expected -0.1, missing expectations. The chart below visualizes how CKPT has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
No Data
You can ask Aime
No Data
